What is Cytek Biosciences, Inc.'s market cap?

Cytek Biosciences, Inc. (CTKB) has a market capitalization of $569.5M and trades on NASDAQ.

What is Cytek Biosciences, Inc.'s revenue and profitability?

Cytek Biosciences, Inc. generated $204.2M in trailing twelve-month revenue with a net loss of $74.0M, representing a net margin of -36.2%. Gross margin stands at 51.7%, with free cash flow of -$12.7M. These figures are based on the Q1 2026 filing.

Who are Cytek Biosciences, Inc.'s competitors?

Cytek Biosciences, Inc.'s key competitors include Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific, and others. These companies compete in similar markets and product categories.

What subsidiaries does Cytek Biosciences, Inc. have?

Cytek Biosciences, Inc.'s subsidiaries include Amnis, Guava.

Where is Cytek Biosciences, Inc. headquartered?

Cytek Biosciences, Inc. is headquartered in United States of America and employs approximately 637 people. It has been publicly traded since 2021.

Cytek Biosciences, Inc.

CTKB

Cytek Biosciences is a leading cell analysis solutions company that develops next-generation research and clinical tools for biomedical research and clinical applications.

Market cap

$569.52M+26.7%

Revenue$204.2M+3.6%

Net income-$74.0M-173%

Free cash flow-$12.7M-173%

EPS (diluted)-$0.57-171%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$44.1MMiss by $98.3K EPS-$0.12Miss by $0.04

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$47.3M

EPS estimate-$0.02

Financials

Q1 2026

Income statement

See full

Revenue$44.1M+6.5%

Gross profit$21.3M+5.4%

Operating income-$18.5M-23.3%

Net income-$18.9M-65.5%

EPS (diluted)-$0.15-66.7%

Balance sheet

See full

Cash & equivalents$31.8M-66.6%

Total debt$16.8M+40.9%

Total equity$327.6M-13.7%

Total assets$449.1M-6.9%

Cash flow

See full

Operating cash flow-$2.7M-2,089%

CapEx$2.2M+155%

Free cash flow-$4.9M-403%

Valuation & ratios

Valuation

See full

Market cap$569.52M+26.7%

Enterprise value$554.48M+32.7%

P/S2.8×+0.4×

Profitability

See full

Gross margin51.7%-3.2pp

Operating margin-21.5%—

Net margin-36.2%—

FCF margin-6.2%-15.1pp

Returns & leverage

See full

Return on equity-20.9%—

Debt / equity0.1×0.0×

Current ratio4.7×-0.9×

Segments

By geography

See full

EMEA$10.8M-6.9%

APAC$7.8M-12.8%

Other$1.2M-50.0%

By segment

See full

Reportable Segment$44.1M+6.5%

By product

See full

Service$15.4M+15.1%

Competitors

By market cap

Thermo Fisher Scientific$207.93B+13.6%

Danaher$138.14B-4.9%

Becton, Dickinson and Company$43.8B-16.5%

Agilent Technologies$38.9B+14.7%

Revvity$12.1B+7.6%

Cytek Biosciences, Inc.$569.5M+19.9%

Standard BioTools Inc.$303.2M-40.9%

ADV

Advanced Biomed Inc. Common Stock$23.7M+106%

By revenue growth

Agilent Technologies+9.1%

Becton, Dickinson and Company+6.4%

Thermo Fisher Scientific+5.6%

Revvity+4.8%

Danaher+4.6%

Cytek Biosciences, Inc.+3.6%

By net margin

Agilent Technologies19.55%+2.0pp

Danaher15.95%+1.7pp

Thermo Fisher Scientific15.19%0.0pp

Revvity8.26%-2.1pp

Becton, Dickinson and Company5.33%-2.1pp

Cytek Biosciences, Inc.-36.25%-22.5pp

Profile

Cytek Biosciences is a leading cell analysis solutions company that develops next-generation research and clinical tools for biomedical research and clinical applications. The company utilizes its proprietary Full Spectrum Profiling (FSP) technology to provide high-resolution, high-content single-cell analysis by leveraging fluorescence signatures from multiple lasers. Its platform enables scientists to phenotype and isolate rare cell populations with high sensitivity, addressing limitations in conventional flow cytometry.

Competitive position

A leading innovator in spectral flow cytometry that differentiates itself through high-parameter multiplexing and superior sensitivity at a lower cost for performance compared to legacy systems.

GeographiesNorth America, Europe, Asia-Pacific

Customer segmentsBiopharmaceutical companies, Academic institutions, Clinical laboratories, Contract Research Organizations

Business modelHardware sales, Consumables and reagents, Service and maintenance

SuppliersLaser and optical component manufacturers, Electronic component suppliers, Chemical and reagent raw material providers

CustomersDrug discovery teams, Immunotherapy researchers, Oncology clinics, Infectious disease researchers

CountryUnited States of America

Listed2021

Employees637.0

CEOWenbin Jiang

SectorHealthcare

IndustryMedical - Devices

Websitecytekbio.com

FilingsSEC EDGAR

Ask your AI about Cytek Biosciences, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s market cap?: Cytek Biosciences, Inc. (CTKB) has a market capitalization of $569.5M and trades on NASDAQ.
What is Cytek Biosciences, Inc.'s revenue and profitability?: Cytek Biosciences, Inc. generated $204.2M in trailing twelve-month revenue with a net loss of $74.0M, representing a net margin of -36.2%. Gross margin stands at 51.7%, with free cash flow of -$12.7M. These figures are based on the Q1 2026 filing.
Who are Cytek Biosciences, Inc.'s competitors?: Cytek Biosciences, Inc.'s key competitors include Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific, and others. These companies compete in similar markets and product categories.
What subsidiaries does Cytek Biosciences, Inc. have?: Cytek Biosciences, Inc.'s subsidiaries include Amnis, Guava.
Where is Cytek Biosciences, Inc. headquartered?: Cytek Biosciences, Inc. is headquartered in United States of America and employs approximately 637 people. It has been publicly traded since 2021.